aibioINTI Inhibitor Therapeutics Inc.
Inhibitor Therapeutics (INTI) news
Top story · Sep 18, 2026 · SEC filing 8-K
Inhibitor Therapeutics reports a leadership change
On September 15, 2026, Inhibitor Therapeutics, Inc., a Delaware corporation (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”).
Latest Inhibitor Therapeutics news
We have not published a story on Inhibitor Therapeutics yet. When there is news, it will appear here.
Inhibitor Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.7 million | $1.8 million |
| Net income (loss) | -$3.3 million | -$3.3 million |
| Cash from operations | -$3.2 million | -$3.2 million |
| Cash and equivalents | $2.4 million | $5.6 million |
Questions about Inhibitor Therapeutics
What is the ticker symbol of Inhibitor Therapeutics?
Inhibitor Therapeutics Inc. trades under the ticker INTI on OTC.
Where is Inhibitor Therapeutics listed?
Inhibitor Therapeutics Inc. is listed on OTC.
What is the SEC CIK of Inhibitor Therapeutics?
The SEC Central Index Key (CIK) for Inhibitor Therapeutics Inc. is 1042418. Its filings are on SEC EDGAR.
How many shares does Inhibitor Therapeutics have outstanding?
173,791,968 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Inhibitor Therapeutics listed under?
Our directory records Inhibitor Therapeutics Inc. under United States.
What does Inhibitor Therapeutics do?
Our directory classifies Inhibitor Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Inhibitor Therapeutics?
The ISIN recorded for Inhibitor Therapeutics Inc. is US45720M1053.
Does aibio.space cover Inhibitor Therapeutics?
aibio.space lists Inhibitor Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Inhibitor Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Inhibitor Therapeutics profitable?
Inhibitor Therapeutics Inc. reported a net loss of $3.3 million for the fiscal year ended Dec 31, 2025, and used $3.2 million of cash in operations, per its annual report to the SEC.
How much does Inhibitor Therapeutics spend on research and development?
$1.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Inhibitor Therapeutics have?
$515,758 in cash at Jun 30, 2026, per its 10-Q.
What is Inhibitor Therapeutics's market cap?
We do not publish live share prices. In its annual report, Inhibitor Therapeutics Inc. put the market value of shares held by non-affiliates (public float) at $3.3 million as of Jun 30, 2025.
Is Inhibitor Therapeutics a smaller reporting company?
SEC records list Inhibitor Therapeutics Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company.
Where is Inhibitor Therapeutics headquartered?
SEC records list its business address as 4830 W. KENNEDY BLVD., TAMPA, FL, 33609.
Investor discussion: Inhibitor Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Inhibitor Therapeutics, Inc.
- CIK
- 1042418
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- INTI (OTC)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 4830 W. KENNEDY BLVD., TAMPA, FL, 33609
- Phone
- (813) 766-2462
- Shares outstanding
- 173,791,968 as of 2026-08-14 (10-Q filed 2026-08-14)
- Former names
- HedgePath Pharmaceuticals, Inc.; COMMONWEALTH BIOTECHNOLOGIES INC
Recent filings
Listing details
- Company
- Inhibitor Therapeutics Inc.
- Ticker
- INTI
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US45720M1053
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction